The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?

Spondylarthritis (SpA) is an inflammatory rheumatic disease associated with increased incidence of major adverse cardiovascular events (MACEs). Recently, Paramarta et al. proposed the use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis to target certain inflammatory pathways. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Omarjee, Loukman, Jaquinandi, Vincent, Mahe, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732514/
https://www.ncbi.nlm.nih.gov/pubmed/29246242
http://dx.doi.org/10.1186/s12967-017-1334-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732514/
https://www.ncbi.nlm.nih.gov/pubmed/29246242
http://dx.doi.org/10.1186/s12967-017-1334-1

Ejemplares similares